within Pharmacolibrary.Drugs.ATC.A;

model A07AX03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.0,
    adminDuration  = 600,
    adminMass      = 200 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A07AX03</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Nifuroxazide is a nitrofuran antibacterial agent used as an intestinal antiseptic, primarily for the treatment of acute diarrhea caused by susceptible bacteria. It acts locally in the gut with minimal systemic absorption. It is approved and used in some countries for acute diarrheal diseases.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic data from published literature indicate that nifuroxazide is minimally absorbed from the gastrointestinal tract in healthy adults. Systemic exposure is negligible in both adult and pediatric subjects.</p><h4>References</h4><ol><li><p>Labaune, JP, et al., &amp; Byrne, R (1986). Comparative physiological disposition of two nitrofuran anti-microbial agents. <i>Biopharmaceutics &amp; drug disposition</i> 7(5) 431–441. DOI:<a href=\"https://doi.org/10.1002/bdd.2510070504\">10.1002/bdd.2510070504</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/3779034/\">https://pubmed.ncbi.nlm.nih.gov/3779034</a></p></li><li><p>Saber, S, et al., &amp; Khodir, AE (2022). Nifuroxazide-loaded cubosomes exhibit an advancement in pulmonary delivery and attenuate bleomycin-induced lung fibrosis by regulating the STAT3 and NF-κB signaling: A new challenge for unmet therapeutic needs. <i>Biomedicine &amp; pharmacotherapy = Biomedecine &amp; pharmacotherapie</i> 148 112731–None. DOI:<a href=\"https://doi.org/10.1016/j.biopha.2022.112731\">10.1016/j.biopha.2022.112731</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35220029/\">https://pubmed.ncbi.nlm.nih.gov/35220029</a></p></li><li><p>Su, X, et al., &amp; Ye, T (2023). Design, synthesis and biological evaluation of novel diarylacylhydrazones derivatives for the efficient treatment of idiopathic pulmonary fibrosis. <i>European journal of medicinal chemistry</i> 245(Pt 2) 114918–None. DOI:<a href=\"https://doi.org/10.1016/j.ejmech.2022.114918\">10.1016/j.ejmech.2022.114918</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36401884/\">https://pubmed.ncbi.nlm.nih.gov/36401884</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A07AX03;
